# Hypertension FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypertension

> 6 upcoming FDA catalysts in hypertension: Foundayo (orforglipron calcium, LLY) on September 2027 (primary completion); Foundayo (orforglipron calcium, LLY) on Sep to Dec 2027 (topline data readout); Foundayo (orforglipron calcium, LLY) on September 2027 (primary completion); Foundayo (orforglipron calcium, LLY) on Sep to Dec 2027 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 28, 2025 | [Lcz primary completion](https://sec-api.dev/pdufa/lcz) | NVS | Hypertension | completed | "NCT06236061 (Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06236061)) |
| December 30, 2025 | [Lorundrostat primary completion](https://sec-api.dev/pdufa/lorundrostat) | MLYS | Hypertension | completed | "NCT05968430 (Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05968430)) |
| January 12, 2026 | [Tonlamarsen primary completion](https://sec-api.dev/pdufa/tonlamarsen) | KARD | Hypertension | completed | "NCT06864104 (A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Kardigan, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864104)) |
| March 9, 2026 | [Lorundrostat NDA/BLA acceptance](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension | completed | "On March 9, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing U.S. Food and Drug Administration (FDA) acceptance of its New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and topline results from the Company's Phase 2 Explore-OSA exploratory trial." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm)) |
| September 17, 2026 | [QCZ484 primary completion](https://sec-api.dev/pdufa/qcz484) | NVS | Hypertension | completed | "NCT06857955 (A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06857955)) |
| Sep to Dec 2026 | [QCZ484 topline data readout](https://sec-api.dev/pdufa/qcz484) | NVS | Hypertension | scheduled | "NCT06857955 (A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06857955)) |
| September 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06948422 (A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948422)) |
| Sep to Dec 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06948422 (A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948422)) |
| September 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06952530 (A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952530)) |
| Sep to Dec 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06952530 (A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952530)) |
| April 2028 | [Aln-agt01 rvr primary completion](https://sec-api.dev/pdufa/aln-agt01-rvr) | ALNY | Hypertension | scheduled | "NCT07553442 (A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-01 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553442)) |
| Apr to Jul 2028 | [Aln-agt01 rvr topline data readout](https://sec-api.dev/pdufa/aln-agt01-rvr) | ALNY | Hypertension | scheduled | "NCT07553442 (A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-01 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553442)) |

## Drugs

- [Lcz](https://sec-api.dev/pdufa/lcz) (NVS)
- [Lorundrostat](https://sec-api.dev/pdufa/lorundrostat) (MLYS)
- [Tonlamarsen](https://sec-api.dev/pdufa/tonlamarsen) (KARD)
- [QCZ484](https://sec-api.dev/pdufa/qcz484) (NVS)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [Aln-agt01 rvr](https://sec-api.dev/pdufa/aln-agt01-rvr) (ALNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypertension.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypertension FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypertension

```bibtex
@misc{secapidev_indications_hypertension_20261116,
  title        = {Hypertension FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypertension}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypertension_20261116","title":"Hypertension FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypertension","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
